A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects With Familial Adenomatous Polyposis
Latest Information Update: 05 Feb 2025
At a glance
- Drugs Guselkumab (Primary)
- Indications Familial adenomatous polyposis
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 14 Jul 2022 Status changed from active, no longer recruiting to completed.
- 02 Dec 2021 Planned End Date changed from 28 Mar 2022 to 13 Sep 2022.
- 11 Aug 2021 Planned primary completion date changed from 30 Jul 2021 to 13 Sep 2021.